Home › Kanser sa Prostate › Tennessee › Nashville
Pag-aaral pangklinika para sa Kanser sa Prostate sa Nashville, TN
Isang pag-aaral para sa Kanser sa Prostate ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Nashville. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Nagre-recruitPhase 1/2
- GSK Investigational Site, Nashville
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Nagre-recruitPhase 3
- Urology Associates, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 2
- SCRI Oncology Partners, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Nagre-recruitPhase 1
- Tennessee Oncology, Nashville
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Nashville
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
- Urology Associates, Nashville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Nagre-recruitPhase 3
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Medical Oncology & Hematology Clinic, Nashville
- Tennessee Oncology, PLLC - Nashville Saint Thomas West, Nashville
- at 7 pa
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1
- Tennessee Oncology, Nashville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Nagre-recruitPhase 3
- Sarah Cannon Research Institute Oncology Partners, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Nagre-recruitPhase 3
- Research Site, Nashville
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Nagre-recruitPhase 2
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Nagre-recruitPhase 3
- SCRI Oncology Partners ( Site 0074), Nashville
- Henry-Joyce Cancer Clinic ( Site 0042), Nashville
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Nagre-recruitPhase 1
- Sarah Cannon Research Institute Oncology Partners, Nashville
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Nagre-recruitPhase 3
- Urology Associates of Nashville, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Center, Nashville
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Nagre-recruitPhase 2
- Tennessee Oncology Nashville, Nashville
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1
- SCRI Oncology Partners, Nashville
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Nagre-recruitPhase 3
- Research Site, Nashville
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Nagre-recruitPhase 2
- Sarah Cannon Research Institute, Nashville
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1
- United States Oncology Regulatory Affairs Corporate Office, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Nagre-recruitPhase 2
- Henry-Joyce Cancer Clinic, Nashville
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Nagre-recruitPhase 1
- Sarah Cannon Research, Nashville
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Tennessee Oncology PLLC, Nashville
PSMA PET Combined With MRI for the Detection of PCa
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
- Urology Associates of Nashville, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Nagre-recruitPhase 1
- Investigative Site #102, Nashville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Nagre-recruitPhase 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Nagre-recruitPhase 1
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Sarah Cannon Research Institute, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Nagre-recruitPhase 1
- Urology Associates PC, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 136, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Nashville
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Nagre-recruitPhase 3
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #6, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Nagre-recruitPhase 1/2
- SCRI Oncology Partners, Nashville
Pag-aaral para sa Kanser sa Prostate sa ibang lungsod
- New York City, NY103 pag-aaral
- Houston, TX76 pag-aaral
- Los Angeles, CA61 pag-aaral
- Boston, MA59 pag-aaral
- St. Louis, MO46 pag-aaral
- Chicago, IL45 pag-aaral
- San Francisco, CA45 pag-aaral
- Philadelphia, PA44 pag-aaral
- Baltimore, MD43 pag-aaral
- Seattle, WA42 pag-aaral
- Washington, DC38 pag-aaral
- Dallas, TX36 pag-aaral
Iba pang pag-aaral sa Nashville
- Non-Small Cell Lung Cancer97 pag-aaral
- Kanser sa Suso81 pag-aaral
- Metastatic Cancer70 pag-aaral
- Colorectal Cancer69 pag-aaral
- Kanser (lahat ng uri)65 pag-aaral
- Kanser sa Ovary49 pag-aaral
- Kanser sa Baga40 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg39 pag-aaral
- Kanser sa Pancreas39 pag-aaral
- Kanser ng Endometrium38 pag-aaral
- Melanoma33 pag-aaral
- Multiple Myeloma32 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.